Quantum Biopharma Ltd QNTM

$2.20 -0.01 (-0.45%)

Valuation

Market cap
18,278,000
Revenue TTM
$0
Net income TTM
$-26,180,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
40,345
Avg volume
155,990
Day's range
$2.17 – $2.25
Shares out
8,087,000
Stochastic %K
29%
Beta
0.51
Analysts
Strong Buy
Price target
$21.75

Price

Company profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of de...

Show more

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
833-304-0323
Website
https://www.quantumbiopharma.com
Address
1 Adelaide Street East, Suite 801, Toronto, Canada

Latest news

Stocktwits

NetworkNewsWire Nov 4, 6:21 PM
$QNTM Advances Broad Strategy Anchored by Science, Disciplined Growth https://ibn.fm/zc7ck
0 replies
Rambler1111 Nov 4, 2:55 AM
$QNTM I Believe we are going to see an Unbuzzed IPO soon. They have a really bright star as a CEO running the show. I can’t believe that he has been sitting still since his appointment as CEO. In a couple announcements the past year it was mentioned that Unbuzzed was shooting to do an IPO 3rd or 4th quarter. They got the right guy who has a rolodex full of famous people to help get the word out. End of the year is getting close now it’s in Zappy’s hands to launch. Let’s getter done.
1 replies
jtcdub Nov 3, 12:06 PM
$QNTM 🤔
0 replies
Rambler1111 Nov 3, 3:17 AM
$QNTM Whens Unbuzzed gonna launch? So far it’s been just a soft launch and getting ready to scale up. When’s this going together rolling? Let’s gohhhh !!!!!
1 replies
NetworkNewsWire Nov 2, 5:59 PM
$QNTM Draws ‘Men’s Fitness’ Spotlight as Unbuzzd Trial Shows Early Promise https://ibn.fm/1Nve1
1 replies
FickleFin Nov 2, 1:58 PM
$QNTM FROM FV PHARMA to FSD PHARMA to QUANTUM BIOPHARMA.. Changed directions every time, never finished any milestones. Same guy(s) same patterns. over promises and under delivers. Rue to STEAL from retail. https://youtu.be/EsXpITmQZ_I?is=Dm9Jhjt6IEd8mV6D
1 replies
Merlintrader Nov 1, 4:36 PM
$QNTM closed the week at $2.38 (+6.3% w/w, -2.5% Friday), below the 50-day SMA ($3.12) and below the 200-day ($3.88). RSI14 35.1. Support $2.09, resistance $3.49 (20-day range, bottom). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/quantum-biopharma-stock-hub/
0 replies
NetworkNewsWire Oct 30, 5:15 PM
InvestorNewsBreaks – $QNTM Taps Thermo Fisher’s Clinical Research Business for Lucid-MS Trial https://ibn.fm/CTkvH
0 replies